Search Results - "Aref, Amir R"

3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade by Aref, Amir R, Campisi, Marco, Ivanova, Elena, Portell, Andrew, Larios, Dalia, Piel, Brandon P, Mathur, Natasha, Zhou, Chensheng, Coakley, Raven Vlahos, Bartels, Alan, Bowden, Michaela, Herbert, Zach, Hill, Sarah, Gilhooley, Sean, Carter, Jacob, Cañadas, Israel, Thai, Tran C, Kitajima, Shunsuke, Chiono, Valeria, Paweletz, Cloud P, Barbie, David A, Kamm, Roger D, Jenkins, Russell W

“…Microfluidic culture has the potential to revolutionize cancer diagnosis and therapy. Indeed, several microdevices are being developed specifically for…”
Get more information

Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor by Christensen, Camilla L., Kwiatkowski, Nicholas, Abraham, Brian J., Carretero, Julian, Al-Shahrour, Fatima, Zhang, Tinghu, Chipumuro, Edmond, Herter-Sprie, Grit S., Akbay, Esra A., Altabef, Abigail, Zhang, Jianming, Shimamura, Takeshi, Capelletti, Marzia, Reibel, Jakob B., Cavanaugh, Jillian D., Gao, Peng, Liu, Yan, Michaelsen, Signe R., Poulsen, Hans S., Aref, Amir R., Barbie, David A., Bradner, James E., George, Rani E., Gray, Nathanael S., Young, Richard A., Wong, Kwok-Kin

“…Small cell lung cancer (SCLC) is an aggressive disease with high mortality, and the identification of effective pharmacological strategies to target SCLC…”
Get full text

Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade by Rashidian, Mohammad, LaFleur, Martin W., Verschoor, Vincent L., Dongre, Anushka, Zhang, Yun, Nguyen, Thao H., Kolifrath, Stephen, Aref, Amir R., Lau, Christie J., Paweletz, Cloud P., Bu, Xia, Freeman, Gordon J., Barrasaf, M. Inmaculad, Weinberg, Robert A., Sharpe, Arlene H., Ploegh, Hidde L.

“…Immunotherapy using checkpoint-blocking antibodies against PD-1 has produced impressive results in a wide range of cancers. However, the response remains…”
Get full text

Carbon nanotubes part II: a remarkable carrier for drug and gene delivery by Karimi, Mahdi, Solati, Navid, Ghasemi, Amir, Estiar, Mehrdad Asghari, Hashemkhani, Mahshid, Kiani, Parnian, Mohamed, Elmira, Saeidi, Ahad, Taheri, Mahdiar, Avci, Pinar, Aref, Amir R, Amiri, Mohammad, Baniasadi, Fazel, Hamblin, Michael R

“…Carbon nanotubes (CNT) have recently been studied as novel and versatile drug and gene delivery vehicles. When CNT are suitably functionalized, they can…”
Get more information

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors by Tan, Li, Wang, Jun, Tanizaki, Junko, Huang, Zhifeng, Aref, Amir R, Rusan, Maria, Zhu, Su-Jie, Zhang, Yiyun, Ercan, Dalia, Liao, Rachel G, Capelletti, Marzia, Zhou, Wenjun, Hur, Wooyoung, Kim, NamDoo, Sim, Taebo, Gaudet, Suzanne, Barbie, David A, Yeh, Jing-Ruey Joanna, Yun, Cai-Hong, Hammerman, Peter S, Mohammadi, Moosa, Jänne, Pasi A, Gray, Nathanael S

“…The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation…”
Get full text

Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth by Barbie, Thanh U, Alexe, Gabriela, Aref, Amir R, Li, Shunqiang, Zhu, Zehua, Zhang, Xiuli, Imamura, Yu, Thai, Tran C, Huang, Ying, Bowden, Michaela, Herndon, John, Cohoon, Travis J, Fleming, Timothy, Tamayo, Pablo, Mesirov, Jill P, Ogino, Shuji, Wong, Kwok-Kin, Ellis, Matthew J, Hahn, William C, Barbie, David A, Gillanders, William E

“…Triple-negative breast cancers (TNBCs) are a heterogeneous set of cancers that are defined by the absence of hormone receptor expression and HER2…”
Get full text

Screening therapeutic EMT blocking agents in a three-dimensional microenvironment by Aref, Amir R, Huang, Ruby Yun-Ju, Yu, Weimiao, Chua, Kian-Ngiap, Sun, Wei, Tu, Ting-Yuan, Bai, Jing, Sim, Wen-Jing, Zervantonakis, Ioannis K, Thiery, Jean Paul, Kamm, Roger D

“…Epithelial-mesenchymal transition (EMT) plays a critical role in the early stages of dissemination of carcinoma leading to metastatic tumors, which are…”
Get full text

Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade by Safaeifard, Fateme, Goliaei, Bahram, Aref, Amir R, Foroughmand-Araabi, Mohammad-Hadi, Goliaei, Sama, Lorch, Jochen, Jenkins, Russell W, Barbie, David A, Shariatpanahi, Seyed Peyman, Rüegg, Curzio

“…Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), two clinically relevant targets for the immunotherapy of…”
Get full text

Complementary effects of ciclopirox olamine, a prolyl hydroxylase inhibitor and sphingosine 1-phosphate on fibroblasts and endothelial cells in driving capillary sprouting by Lim, Sei Hien, Kim, Choong, Aref, Amir R, Kamm, Roger D, Raghunath, Michael

“…Capillary sprouting, a key step of neoangiogenesis in wound healing and tumor growth, also represents a therapeutic target for tissue repair. It requires…”
Get full text

Nanomedicine and advanced technologies for burns: Preventing infection and facilitating wound healing by Mofazzal Jahromi, Mirza Ali, Sahandi Zangabad, Parham, Moosavi Basri, Seyed Masoud, Sahandi Zangabad, Keyvan, Ghamarypour, Ameneh, Aref, Amir R., Karimi, Mahdi, Hamblin, Michael R.

“…According to the latest report from the World Health Organization, an estimated 265,000 deaths still occur every year as a direct result of burn injuries. A…”
Get full text

Microfluidic systems for stem cell-based neural tissue engineering by Karimi, Mahdi, Bahrami, Sajad, Mirshekari, Hamed, Basri, Seyed Masoud Moosavi, Nik, Amirala Bakhshian, Aref, Amir R, Akbari, Mohsen, Hamblin, Michael R

“…Neural tissue engineering aims at developing novel approaches for the treatment of diseases of the nervous system, by providing a permissive environment for…”
Get more information

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma by Sade-Feldman, Moshe, Yizhak, Keren, Bjorgaard, Stacey L., Ray, John P., de Boer, Carl G., Jenkins, Russell W., Lieb, David J., Chen, Jonathan H., Frederick, Dennie T., Barzily-Rokni, Michal, Freeman, Samuel S., Reuben, Alexandre, Hoover, Paul J., Villani, Alexandra-Chloé, Ivanova, Elena, Portell, Andrew, Lizotte, Patrick H., Aref, Amir R., Eliane, Jean-Pierre, Hammond, Marc R., Vitzthum, Hans, Blackmon, Shauna M., Li, Bo, Gopalakrishnan, Vancheswaran, Reddy, Sangeetha M., Cooper, Zachary A., Paweletz, Cloud P., Barbie, David A., Stemmer-Rachamimov, Anat, Flaherty, Keith T., Wargo, Jennifer A., Boland, Genevieve M., Sullivan, Ryan J., Getz, Gad, Hacohen, Nir

“…Treatment of cancer has been revolutionized by immune checkpoint blockade therapies. Despite the high rate of response in advanced melanoma, the majority of…”
Get full text

Mesenchymal stem cells induce PD‐L1 expression through the secretion of CCL5 in breast cancer cells by Aboulkheyr Es, Hamidreza, Bigdeli, Bahareh, Zhand, Sareh, Aref, Amir R., Thiery, Jean P., Warkiani, Majid E.

“…Various factors in the tumor microenvironment (TME) regulate the expression of PD‐L1 in cancer cells. In TME, mesenchymal stem cells (MSCs) play a crucial role…”
Get full text

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment by Koyama, Shohei, Akbay, Esra A, Li, Yvonne Y, Aref, Amir R, Skoulidis, Ferdinandos, Herter-Sprie, Grit S, Buczkowski, Kevin A, Liu, Yan, Awad, Mark M, Denning, Warren L, Diao, Lixia, Wang, Jing, Parra-Cuentas, Edwin R, Wistuba, Ignacio I, Soucheray, Margaret, Thai, Tran, Asahina, Hajime, Kitajima, Shunsuke, Altabef, Abigail, Cavanaugh, Jillian D, Rhee, Kevin, Gao, Peng, Zhang, Haikuo, Fecci, Peter E, Shimamura, Takeshi, Hellmann, Matthew D, Heymach, John V, Hodi, F Stephen, Freeman, Gordon J, Barbie, David A, Dranoff, Glenn, Hammerman, Peter S, Wong, Kwok-Kin

“…STK11/LKB1 is among the most commonly inactivated tumor suppressors in non-small cell lung cancer (NSCLC), especially in tumors harboring KRAS mutations. Many…”
Get full text

Targeting TBK1 to overcome resistance to cancer immunotherapy by Sun, Yi, Revach, Or-yam, Anderson, Seth, Kessler, Emily A., Wolfe, Clara H., Jenney, Anne, Mills, Caitlin E., Robitschek, Emily J., Davis, Thomas G. R., Kim, Sarah, Fu, Amina, Ma, Xiang, Gwee, Jia, Tiwari, Payal, Du, Peter P., Sindurakar, Princy, Tian, Jun, Mehta, Arnav, Schneider, Alexis M., Yizhak, Keren, Sade-Feldman, Moshe, LaSalle, Thomas, Sharova, Tatyana, Xie, Hongyan, Liu, Shuming, Michaud, William A., Saad-Beretta, Rodrigo, Yates, Kathleen B., Iracheta-Vellve, Arvin, Spetz, Johan K. E., Qin, Xingping, Sarosiek, Kristopher A., Zhang, Gao, Kim, Jong Wook, Su, Mack Y., Cicerchia, Angelina M., Rasmussen, Martin Q., Klempner, Samuel J., Juric, Dejan, Pai, Sara I., Miller, David M., Giobbie-Hurder, Anita, Chen, Jonathan H., Pelka, Karin, Frederick, Dennie T., Stinson, Susanna, Ivanova, Elena, Aref, Amir R., Paweletz, Cloud P., Barbie, David A., Sen, Debattama R., Fisher, David E., Corcoran, Ryan B., Hacohen, Nir, Sorger, Peter K., Flaherty, Keith T., Boland, Genevieve M., Manguso, Robert T., Jenkins, Russell W.

“…Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking 1…”
Get full text

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma by Sade-Feldman, Moshe, Yizhak, Keren, Bjorgaard, Stacey L., Ray, John P., de Boer, Carl G., Jenkins, Russell W., Lieb, David J., Chen, Jonathan H., Frederick, Dennie T., Barzily-Rokni, Michal, Freeman, Samuel S., Reuben, Alexandre, Hoover, Paul J., Villani, Alexandra-Chloé, Ivanova, Elena, Portell, Andrew, Lizotte, Patrick H., Aref, Amir R., Eliane, Jean-Pierre, Hammond, Marc R., Vitzthum, Hans, Blackmon, Shauna M., Li, Bo, Gopalakrishnan, Vancheswaran, Reddy, Sangeetha M., Cooper, Zachary A., Paweletz, Cloud P., Barbie, David A., Stemmer-Rachamimov, Anat, Flaherty, Keith T., Wargo, Jennifer A., Boland, Genevieve M., Sullivan, Ryan J., Getz, Gad, Hacohen, Nir

Get full text

Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity by Mahabady, Mahmood K., Mirzaei, Sepideh, Saebfar, Hamidreza, Gholami, Mohammad H., Zabolian, Amirhossein, Hushmandi, Kiavash, Hashemi, Farid, Tajik, Fatemeh, Hashemi, Mehrdad, Kumar, Alan P., Aref, Amir R., Zarrabi, Ali, Khan, Haroon, Hamblin, Michael R., Nuri Ertas, Yavuz, Samarghandian, Saeed

“…The identification of agents that can reverse drug resistance in cancer chemotherapy, and enhance the overall efficacy is of great interest. Paclitaxel (PTX)…”
Get full text

Carbon nanotubes in microfluidic lab-on-a-chip technology: current trends and future perspectives by Ghasemi, Amir, Amiri, Hamed, Zare, Hossein, Masroor, Maryam, Hasanzadeh, Akbar, Beyzavi, Ali, Aref, Amir R., Karimi, Mahdi, Hamblin, Michael R.

“…Advanced nanomaterials such as carbon nanotubes (CNTs) display unprecedented properties such as strength, electrical conductance, thermal stability, and…”
Get full text

Carbon nanotubes part I: preparation of a novel and versatile drug-delivery vehicle by Karimi, Mahdi, Solati, Navid, Amiri, Mohammad, Mirshekari, Hamed, Mohamed, Elmira, Taheri, Mahdiar, Hashemkhani, Mahshid, Saeidi, Ahad, Estiar, Mehrdad Asghari, Kiani, Parnian, Ghasemi, Amir, Basri, Seyed Masoud Moosavi, Aref, Amir R, Hamblin, Michael R

“…It is 23 years since carbon allotrope known as carbon nanotubes (CNT) was discovered by Iijima, who described them as "rolled graphite sheets inserted into…”
Get more information

Integrated use of bioinformatic resources reveals that co-targeting of histone deacetylases, IKBK and SRC inhibits epithelial-mesenchymal transition in cancer by Barneh, Farnaz, Mirzaie, Mehdi, Nickchi, Payman, Tan, Tuan Zea, Thiery, Jean Paul, Piran, Mehran, Salimi, Mona, Goshadrou, Fatemeh, Aref, Amir R, Jafari, Mohieddin

“…Abstract With the advent of high-throughput technologies leading to big data generation, increasing number of gene signatures are being published to predict…”
Get full text